Assenagon Asset Management S.A. Buys Shares of 341,800 Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Assenagon Asset Management S.A. acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 341,800 shares of the biopharmaceutical company's stock, valued at approximately $2,505,000. Assenagon Asset Management S.A. owned 0.21% of Ocular Therapeutix as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of OCUL. Point72 Asset Management L.P. raised its holdings in shares of Ocular Therapeutix by 43.9% in the 4th quarter. Point72 Asset Management L.P. now owns 2,935,924 shares of the biopharmaceutical company's stock valued at $25,073,000 after purchasing an additional 895,304 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Ocular Therapeutix in the 4th quarter valued at about $3,819,000. Artisan Partners Limited Partnership lifted its holdings in shares of Ocular Therapeutix by 26.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock valued at $11,398,000 after purchasing an additional 278,610 shares during the last quarter. Rosalind Advisors Inc. boosted its position in shares of Ocular Therapeutix by 27.5% in the 4th quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock valued at $9,639,000 after purchasing an additional 243,700 shares during the period. Finally, Patient Square Capital LP boosted its position in shares of Ocular Therapeutix by 100.0% in the 4th quarter. Patient Square Capital LP now owns 470,919 shares of the biopharmaceutical company's stock valued at $4,022,000 after purchasing an additional 235,421 shares during the period. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Ocular Therapeutix Stock Performance

OCUL traded down $0.21 during trading on Friday, hitting $8.13. The stock had a trading volume of 935,159 shares, compared to its average volume of 1,439,234. The firm has a market capitalization of $1.29 billion, a P/E ratio of -7.07 and a beta of 1.42. The company has a debt-to-equity ratio of 0.26, a quick ratio of 10.14 and a current ratio of 10.22. Ocular Therapeutix, Inc. has a twelve month low of $5.79 and a twelve month high of $11.78. The company's 50-day moving average price is $7.85 and its 200 day moving average price is $7.85.

Analyst Ratings Changes

Several research analysts have commented on OCUL shares. Needham & Company LLC cut their price target on Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. William Blair initiated coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They issued an "outperform" rating for the company. HC Wainwright reiterated a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Royal Bank Of Canada started coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective on the stock. Finally, JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Ocular Therapeutix has an average rating of "Moderate Buy" and a consensus target price of $16.25.

Insider Activity

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,219 shares of the stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $7.18, for a total value of $152,352.42. Following the completion of the transaction, the insider now owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. This represents a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard L. Md Lindstrom bought 10,000 shares of the firm's stock in a transaction on Thursday, May 8th. The shares were bought at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now directly owns 172,704 shares in the company, valued at approximately $1,202,019.84. This represents a 6.15% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 29,079 shares of company stock valued at $208,739 over the last quarter. Corporate insiders own 2.30% of the company's stock.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.